FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3005802010> ?p ?o ?g. }

• W3005802010 endingPage "163" @default.
• W3005802010 startingPage "157" @default.
• W3005802010 abstract "PurposeMelanoma brain metastases (MBM) occur in ∼50% of melanoma patients. Although both radiation therapy (RT) and immune checkpoint inhibitor (ICI) are used alone or in combination for MBM treatment, the role of this combination and how these treatments could best be sequenced remains unclear.Methods and MaterialsWe conducted a retrospective analysis of patients with resected MBM who underwent treatment with RT, ICI, or a combination of RT and ICI. Among the latter, we specifically investigated the differential gene expression via RNA-sequencing between patients who received RT first then ICI (RT → ICI) versus ICI first then RT (ICI → RT). We used a glycoprotein-transduced syngeneic melanoma mouse model for validation experiments.ResultsWe found that for patients with resected MBM, a combination of RT and ICI confers superior survival compared with RT alone. Specifically, we found that RT → ICI was superior compared with ICI → RT. Transcriptome analysis of resected MBM revealed that the RT → ICI cohort demonstrated deregulation of genes involved in apoptotic signaling and key modulators of inflammation that are most implicated in nuclear factor kappa-light-chain-enhancer of activated B cells signaling. In a preclinical model, we showed that RT followed by anti-programmed death-ligand 1 therapy was superior to the reverse sequence of therapy, supporting the observations we made in patients with MBM.ConclusionsOur study provides initial insights into the optimal sequence of RT and ICI in the treatment of MBM after surgical resection. Prospective studies examining the best sequence of RT and ICI are necessary, and our study contributes to the rationale to pursue these. Melanoma brain metastases (MBM) occur in ∼50% of melanoma patients. Although both radiation therapy (RT) and immune checkpoint inhibitor (ICI) are used alone or in combination for MBM treatment, the role of this combination and how these treatments could best be sequenced remains unclear. We conducted a retrospective analysis of patients with resected MBM who underwent treatment with RT, ICI, or a combination of RT and ICI. Among the latter, we specifically investigated the differential gene expression via RNA-sequencing between patients who received RT first then ICI (RT → ICI) versus ICI first then RT (ICI → RT). We used a glycoprotein-transduced syngeneic melanoma mouse model for validation experiments. We found that for patients with resected MBM, a combination of RT and ICI confers superior survival compared with RT alone. Specifically, we found that RT → ICI was superior compared with ICI → RT. Transcriptome analysis of resected MBM revealed that the RT → ICI cohort demonstrated deregulation of genes involved in apoptotic signaling and key modulators of inflammation that are most implicated in nuclear factor kappa-light-chain-enhancer of activated B cells signaling. In a preclinical model, we showed that RT followed by anti-programmed death-ligand 1 therapy was superior to the reverse sequence of therapy, supporting the observations we made in patients with MBM. Our study provides initial insights into the optimal sequence of RT and ICI in the treatment of MBM after surgical resection. Prospective studies examining the best sequence of RT and ICI are necessary, and our study contributes to the rationale to pursue these." @default.
• W3005802010 created "2020-02-24" @default.
• W3005802010 creator A5003718738 @default.
• W3005802010 creator A5009839688 @default.
• W3005802010 creator A5011722895 @default.
• W3005802010 creator A5019366387 @default.
• W3005802010 creator A5025069765 @default.
• W3005802010 creator A5026088869 @default.
• W3005802010 creator A5034140883 @default.
• W3005802010 creator A5040717966 @default.
• W3005802010 creator A5045127913 @default.
• W3005802010 creator A5052100404 @default.
• W3005802010 creator A5056670989 @default.
• W3005802010 creator A5061676019 @default.
• W3005802010 creator A5062729861 @default.
• W3005802010 creator A5065029455 @default.
• W3005802010 creator A5065443187 @default.
• W3005802010 creator A5076064890 @default.
• W3005802010 creator A5076832426 @default.
• W3005802010 creator A5088959376 @default.
• W3005802010 creator A5090997250 @default.
• W3005802010 date "2020-09-01" @default.
• W3005802010 modified "2023-10-18" @default.
• W3005802010 title "Impact of Sequencing Radiation Therapy and Immune Checkpoint Inhibitors in the Treatment of Melanoma Brain Metastases" @default.
• W3005802010 cites W1991993823 @default.
• W3005802010 cites W2032166347 @default.
• W3005802010 cites W2066711262 @default.
• W3005802010 cites W2117878645 @default.
• W3005802010 cites W2166662937 @default.
• W3005802010 cites W2287384543 @default.
• W3005802010 cites W2401492317 @default.
• W3005802010 cites W2461739654 @default.
• W3005802010 cites W2521278016 @default.
• W3005802010 cites W2565830824 @default.
• W3005802010 cites W2591447948 @default.
• W3005802010 cites W2753065806 @default.
• W3005802010 cites W2753432434 @default.
• W3005802010 cites W2783137027 @default.
• W3005802010 cites W2888298425 @default.
• W3005802010 cites W2903675605 @default.
• W3005802010 cites W4230504710 @default.
• W3005802010 doi "https://doi.org/10.1016/j.ijrobp.2020.01.043" @default.
• W3005802010 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7839060" @default.
• W3005802010 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32057994" @default.
• W3005802010 hasPublicationYear "2020" @default.
• W3005802010 type Work @default.
• W3005802010 sameAs 3005802010 @default.
• W3005802010 citedByCount "22" @default.
• W3005802010 countsByYear W30058020102020 @default.
• W3005802010 countsByYear W30058020102021 @default.
• W3005802010 countsByYear W30058020102022 @default.
• W3005802010 countsByYear W30058020102023 @default.
• W3005802010 crossrefType "journal-article" @default.
• W3005802010 hasAuthorship W3005802010A5003718738 @default.
• W3005802010 hasAuthorship W3005802010A5009839688 @default.
• W3005802010 hasAuthorship W3005802010A5011722895 @default.
• W3005802010 hasAuthorship W3005802010A5019366387 @default.
• W3005802010 hasAuthorship W3005802010A5025069765 @default.
• W3005802010 hasAuthorship W3005802010A5026088869 @default.
• W3005802010 hasAuthorship W3005802010A5034140883 @default.
• W3005802010 hasAuthorship W3005802010A5040717966 @default.
• W3005802010 hasAuthorship W3005802010A5045127913 @default.
• W3005802010 hasAuthorship W3005802010A5052100404 @default.
• W3005802010 hasAuthorship W3005802010A5056670989 @default.
• W3005802010 hasAuthorship W3005802010A5061676019 @default.
• W3005802010 hasAuthorship W3005802010A5062729861 @default.
• W3005802010 hasAuthorship W3005802010A5065029455 @default.
• W3005802010 hasAuthorship W3005802010A5065443187 @default.
• W3005802010 hasAuthorship W3005802010A5076064890 @default.
• W3005802010 hasAuthorship W3005802010A5076832426 @default.
• W3005802010 hasAuthorship W3005802010A5088959376 @default.
• W3005802010 hasAuthorship W3005802010A5090997250 @default.
• W3005802010 hasBestOaLocation W30058020101 @default.
• W3005802010 hasConcept C104317684 @default.
• W3005802010 hasConcept C121608353 @default.
• W3005802010 hasConcept C126322002 @default.
• W3005802010 hasConcept C143998085 @default.
• W3005802010 hasConcept C150194340 @default.
• W3005802010 hasConcept C162317418 @default.
• W3005802010 hasConcept C185592680 @default.
• W3005802010 hasConcept C203014093 @default.
• W3005802010 hasConcept C2776999253 @default.
• W3005802010 hasConcept C2777658100 @default.
• W3005802010 hasConcept C2777701055 @default.
• W3005802010 hasConcept C2780851360 @default.
• W3005802010 hasConcept C502942594 @default.
• W3005802010 hasConcept C509974204 @default.
• W3005802010 hasConcept C55493867 @default.
• W3005802010 hasConcept C71924100 @default.
• W3005802010 hasConcept C8891405 @default.
• W3005802010 hasConceptScore W3005802010C104317684 @default.
• W3005802010 hasConceptScore W3005802010C121608353 @default.
• W3005802010 hasConceptScore W3005802010C126322002 @default.
• W3005802010 hasConceptScore W3005802010C143998085 @default.
• W3005802010 hasConceptScore W3005802010C150194340 @default.
• W3005802010 hasConceptScore W3005802010C162317418 @default.
• W3005802010 hasConceptScore W3005802010C185592680 @default.
• W3005802010 hasConceptScore W3005802010C203014093 @default.

• next